Lasofoxifene tartrate(CAS: 190791-29-8)

Lasofoxifene tartrate (CAS: 190791-29-8) is subject to regulatory guidelines under the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) for hazardous substances. Additionally, it falls under the scope of the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations in the European Union. In the United States, it may be regulated by the Food and Drug Administration (FDA) for pharmaceuticals and the Environmental Protection Agency (EPA) for environmental safety.

In the synthesis of lasofoxifene tartrate (CAS: 190791-29-8), alternative reagents and methods may include the use of similar estrogen agonists such as raloxifene or bazedoxifene. Isomers or analogs of lasofoxifene may also be considered, but thorough structural and functional analysis is required to ensure the desired pharmacological properties are maintained.

The market for lasofoxifene tartrate (CAS: 190791-29-8) is primarily driven by its use as a selective estrogen receptor modulator (SERM) in the treatment of osteoporosis and menopausal symptoms. Research trends are focused on understanding its pharmacokinetics, therapeutic efficacy, and potential side effects. Recent studies are also exploring its role in preventing bone loss and its safety profile in different patient populations.

Waste containing lasofoxifene tartrate (CAS: 190791-29-8) should be collected in appropriate containers and stored separately to prevent contamination. Disposal should follow environmental protection guidelines, typically involving incineration at a licensed waste treatment facility or professional waste disposal. All handling and disposal procedures must comply with local and international regulations, including GHS and REACH guidelines, to ensure safety and environmental protection.